Abstract
Two monoclonal antibodies recognizing non-overlapping epitopes of the PRAME protein were injected into immunocompetent mice to study their influence on the growth of subcutaneous tumor nodes. The B16F10 murine melanoma line, either expressing human PRAME protein or bearing only a vector without PRAME gene, were used as transplants. Each of the antibodies showed the ability to suppress tumor growth of a PRAME-expressing tumour, but not a tumor without PRAME.
Similar content being viewed by others
REFERENCES
Xu, Y., Zou, R., Wang, J., at al., The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer, Cell Prolif., 2020, vol. 53, no. 3, e12770.
Misyurin, V.A., Klin. Onkogematol., Fundam. Issled. Klin. Prakt., 2018, no. 11 (1), pp. 26–33.
Li, J., Yin, J., Zhong, J., et al., Clinicopathological and prognostic significance of PRAME overexpression in human cancer: a meta-analysis, Biomed. Res. Int., 2020, vol. 2020, art. 8828579.
Albertsmeier, M., Altendorf-Hofmann, A., Lindner, L.H., et al., Cancer testis antigens and immunotherapy: expression of PRAME is associated with prognosis in soft tissue sarcoma, Cancers (Basel), 2020.
Al-Khadairi, G. and Decock, J., Cancer testis antigens and immunotherapy: where do we stand in the targeting of PRAME?, Cancers (Basel), 2019, vol. 11, no. 7, p. 984.
Finashutina, Yu.P., Misyurin, A.V., Akhlynina, T.V., et al., Production of purified human recombinant antigen PRAME and specific monoclonal antibodies, Ross. Bioter. Zh., 2015, vol. 14, no. 3, pp. 29–36.
Treshchalina, E.M., Zhukova, O.S., Gerasimova, G.K., et al., Methodical recommendations for preclinical trials of the antitumor activity of drugs, in Rukovodstvo po provedeniyu doklinicheskikh issledovanii lekarstvennykh sredstv (Preclinical Trials Guide), part 1, Mironov, A.N., Bunatyan, N.D., and Vasilyev, A.N., et al., Eds., Moscow: Grif and Co., 2012, pp. 640–654.
Andersen, J.T., Daba, M.B., Berntzen, G., et al., Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding, J. Biol. Chem., 2010, vol. 285, pp. 4826–4836.
Misyurin, V.A., Finashutina, Yu.P., Turba, A.A., et al., Epitope analysis of murine and chimeric monoclonal antibodies recognizing the cancer testis antigen PRAME, Dokl. Biochem. Biophys., 2020, vol. 492, pp. 135–138.
Funding
This study was supported by the Ministry of Science and Higher Education of the Russian Federation (Agreement no. 075-15-2019-1249 dated June 10, 2019), unique project identifier RFMEFI60418X0204).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest. The authors declare that they have no conflict of interest.
Statement on the welfare of animals. All experiments on animals were carried out in accordance with the requirements of the Commission for the Control of the Maintenance and Use of Animals of the FIBC RAS (Minutes no. 117 of February 18, 2020).
Additional information
Translated by M. Batrukova
Rights and permissions
About this article
Cite this article
Solopova, O.N., Finashutina, Y.P., Kasatkina, N.N. et al. Monoclonal Antibodies to PRAME Protein Slow the Development of PRAME-Expressing Tumor. Dokl Biochem Biophys 498, 199–202 (2021). https://doi.org/10.1134/S1607672921030091
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S1607672921030091